{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T09:59:44Z","timestamp":1777802384473,"version":"3.51.4"},"reference-count":12,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[1998,11,1]],"date-time":"1998-11-01T00:00:00Z","timestamp":909878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Child Neurol"],"published-print":{"date-parts":[[1998,11]]},"abstract":"<jats:p>In comparison with phenytoin preparations, which have a pH value of 11, fosphenytoin, a phosphorylated prodrug of phenytoin, has a pH value of only 8.6, which decreases the risk of cardiovascular and cutaneous side effects. The near-neutral pH value of fosphenytoin allows effective intravenous or intramuscular administration. A 1-mg phenytoin equivalent (PE) of fosphenytoin is converted to 1 mg of phenytoin in adults. We describe four infants whose seizures were treated with intravenous fosphenytoin. We had difficulty maintaining therapeutic serum phenytoin levels of 10 to 20 \u03bcg\/mL on doses of 5 to 8 mgPE\/kg\/day, and many bolus doses of 5 to 10 mgPE\/kg or maintenance doses of more than 10 mgPE\/kg\/day were given. Despite increased doses in three out of the four patients, a therapeutic serum phenytoin level was not maintained. From our experience, careful and individual dosing of fosphenytoin in this age group can be considered. (J Child Neurol 1998;13:537-540).<\/jats:p>","DOI":"10.1177\/088307389801301102","type":"journal-article","created":{"date-parts":[[2008,12,24]],"date-time":"2008-12-24T02:13:25Z","timestamp":1230084805000},"page":"537-540","source":"Crossref","is-referenced-by-count":24,"title":["Fosphenytoin in Infants"],"prefix":"10.1177","volume":"13","author":[{"given":"Masanori","family":"Takeoka","sequence":"first","affiliation":[{"name":"Department of Neurology, Pediatric Neurology Service, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalpathy S.","family":"Krishnamoorthy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Pediatric Neurology Service, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teesta B.","family":"Soman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Pediatric Neurology Service, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Verne S.","family":"Caviness","sequence":"additional","affiliation":[{"name":"Department of Neurology, Pediatric Neurology Service, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1998,11,1]]},"reference":[{"key":"atypb1","volume-title":"Prescribing information on Cerebyx (Fosphenytoin Sodium Injection)","author":"Parke-Davis","year":"1996"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6_Suppl_1.3S"},{"key":"atypb3","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/j.1875-9114.1996.tb03646.x","volume":"16","author":"Boucher BA","year":"1996","journal-title":"Pharmacotherapy"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(67)90011-7"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(76)80126-3"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6_Suppl_1.20S"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6_Suppl_1.17S"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/53.22.2707"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05820.x"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6_Suppl_1.14S"},{"key":"atypb11","first-page":"51","volume":"88","author":"Lai CM","year":"1995","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.2.173"}],"container-title":["Journal of Child Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/088307389801301102","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/088307389801301102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:32:40Z","timestamp":1777494760000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/088307389801301102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,11]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1998,11]]}},"alternative-id":["10.1177\/088307389801301102"],"URL":"https:\/\/doi.org\/10.1177\/088307389801301102","relation":{},"ISSN":["0883-0738","1708-8283"],"issn-type":[{"value":"0883-0738","type":"print"},{"value":"1708-8283","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,11]]}}}